Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
- Posted on August 10, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
Aug 10 (Reuters) - Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at up to $1.32 billion, adding an experimental treatment for a rare inherited form of epilepsy that has no approved therapies. The treatment, called ABS-1230, is being developed for KCNT1-related epilepsy, a severe disease that causes frequent seizures and developmental problems
